drug
rolapitant hydrochloride
Marketedupdated 5mo agoby TerSera Therapeutics LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 4, 2027
182 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Jul 14, 2032method-of-use (U-1741)US 9101615
- Oct 9, 2029formulationUS 83615003.0y
- Jan 18, 2029method-of-use (U-1741)US 84708422.3y
- Jan 18, 2029method-of-use (U-1741)US 84708422.3y
- Aug 19, 2028compositionUS 70493201.9y
- Aug 19, 2028compositionUS 70493201.9y
- Apr 4, 2027formulationUS 7563801182d
- Apr 4, 2027method-of-use (U-1741)US 7981905182d
- Apr 4, 2027method-of-use (U-1741)US 7981905182d
- Apr 4, 2027compositionUS 8178550182d
- Apr 4, 2027compositionUS 8178550182d
- Apr 4, 2027method-of-use (U-1741)US 8404702182d
- Apr 4, 2027method-of-use (U-1741)US 8404702182d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that